Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the ...

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan ...

SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00.Invest ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

Roche Holding AG said profit will probably outpace sales growth this year as the Swiss drugmaker works to keep research costs in check and looks for deals to build its pipeline of experimental ...

In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...